Article
Azacitidine-Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia.
The New England journal of medicine - 3 Sept 2026
Fathi Amir T, Perl Alexander E, Fell Geoffrey G, Jonas Brian A, Ragon Brittany K, Mims Alice S, Borate Uma, Mannis Gabriel N, Quillen Karen, Stahl Maximilian, Aubrey Brandon J, Koller Paul, Artz Andrew S, Al Malki Monzr M, Stein Anthony S, Marcucci Guido, Peters Mary Linton B, Graubert Timothy A, Westervelt Peter, Amrein Philip C, Hock Hanno R, Brunner Andrew M, Hobbs Gabriela, Narayan Rupa, Lee Michelle H, Miller Peter G, Watson Alyssa L, Hao Richard, Marola Abigail C, Lombardi-Story Jennifer, Dhaver Shilton, Grunwald Michael R, Chen Yi-Bin, Weinstock Matthew J, Matthews Andrew H, McGovern Ian, Wood Brent L, Hourigan Christopher S, Neuberg Donna S, El-Jawahri Areej, Aldoss Ibrahim
Abstract excerpt
BACKGROUND: Induction chemotherapy has long been a key component of curative therapy for fit patients with acute myeloid leukemia (AML), despite its frequently severe side effects and substantial health care utilization. For patients who are ineligible for induction chemotherapy, hypomethylating therapy plus venetoclax is the standard treatment owing to its efficacy and side-effect profile. METHODS: In this...
Read the complete abstract on PubMedTopics
- Adult
- Aged